Printer Friendly

Two U.S. Patents Extend York Medical's Proprietary Position in Oncology.

MISSISSAUGA, ON, April 29 /CNW-PRN/ - York Medical Inc. (``YM'') is pleased to announce that two U.S. patents have recently been granted on products it has in-licensed from the Centre of Molecular Immunology in Havana, Cuba.

United States patent No. 5,891,996, granted on April 6, 1999, covers the company's new humanized and chimeric monoclonal antibodies (MAbs) that recognize epidermal growth factor receptor (EGF-r) and pharmaceutical compositions containing the antibodies. York Medical's family of MAb-based oncology products includes a diagnostic to EGF-r, a stand-alone therapeutic and a radiolabelled therapeutic.

United States patent No. 5,894,018, granted on April 13, 1999, covers the company's EGF cancer vaccine and pharmaceutical compositions containing autologous EGF and method of treating EGF-dependent diseases. The patent was previously granted in Canada in January of this year and in Japan in September 1998.

``The granting of these patents in the United States extends York Medical's proprietary rights in the area of monoclonal antibodies and supports our position as a leading source of novel anticancer therapies,'' said David G.P. Allan, President and CEO of York Medical Inc. ``With each of the products covered by these patents in or about to enter Phase II clinical trials, we are in a position to offer potential licensees an extensive range of advanced, proprietary anti-cancer products.''

York Medical Inc. is a Canadian licensing and development company formed for the purpose of commercializing innovative life-sciences products and technologies originating in Cuba. All products in development by York Medical are available under license for the major world markets.

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated due to a number of factors. No forward-looking statement is a guarantee of future results or events and one should avoid placing undue reliance on such statements.
COPYRIGHT 1999 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Geographic Code:1USA
Date:Apr 29, 1999
Words:322
Previous Article:North American Technologies Group Receives Major Sales Order, Environmental Award and U.S. Patent.
Next Article:/FROM PR NEWSWIRE 800-682-9599/ TO BUSINESS EDITOR:.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters